Vitiligo, From Physiopathology to Emerging Treatments: A Review

Overview

Journal Dermatol Ther (Heidelb)

Date 2020 Sep 19

PMID 32949337

Citations 19

Authors

Laure Migayron

Katia Boniface

Julien Seneschal

Affiliations

Soon will be listed here.

Abstract

Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes. To date, treatment options for vitiligo patients are limited, lack sustained efficacy, and are mainly based on off-label use of immunosuppressive agents, such as systemic or topical steroids or topical calcineurin inhibitors, in association with the use of ultraviolet light. However, recent insights into the understanding of the immune pathogenesis of the disease have led to the identification of several therapeutic targets and the development of targeted therapies that are now being tested in clinical trials. In this review, based on the physiopathology of the disease, we summarize emerging targets that could be developed for the treatment of vitiligo and discuss recent and ongoing developments of drugs for the management of the disease.

Citing Articles

Dietary Interventions, Supplements, and Plant-Derived Compounds for Adjunct Vitiligo Management: A Review of the Literature.

Diaz M, Tran J, Rose D, Wei A, Lakshmipathy D, Lipner S Nutrients. 2025; 17(2).

PMID: 39861486 PMC: 11767946. DOI: 10.3390/nu17020357.

Comorbidities Associated with Vitiligo: Results from the EpiChron Cohort.

Clemente Hernandez B, Muelas Rives I, Gracia Cazana T, Alvarez Salafranca M, Poblador-Plou B, Laguna-Berna C J Clin Med. 2025; 14(2).

PMID: 39860439 PMC: 11765835. DOI: 10.3390/jcm14020432.

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta-Analysis.

Huang F, Hu D, Fan H, Hu B, Liu Y, Dong W Clin Pharmacol Ther. 2024; 117(3):659-669.

PMID: 39713946 PMC: 11835431. DOI: 10.1002/cpt.3538.

The Anti-Vitiligo Effects of Feshurin In Vitro from and the Mechanism of Action.

Nueraihemaiti M, Deng Z, Kamoldinov K, Chao N, Habasi M, Aisa H Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338414 PMC: 11434855. DOI: 10.3390/ph17091252.

Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.

Yamaguchi H, Yamaguchi Y, Peeva E J Eur Acad Dermatol Venereol. 2024; 39(3):498-511.

PMID: 39258892 PMC: 11851261. DOI: 10.1111/jdv.20311.

References

Fraczek A, Owczarczyk-Saczonek A, Placek W . The Role of T Cells in the Pathogenesis of Vitiligo-A Review of the Current State-Of-The-Art. Int J Mol Sci. 2020; 21(10). PMC: 7278984. DOI: 10.3390/ijms21103552. View

Natarajan V, Ganju P, Singh A, Vijayan V, Kirty K, Yadav S . IFN-γ signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation. Proc Natl Acad Sci U S A. 2014; 111(6):2301-6. PMC: 3926048. DOI: 10.1073/pnas.1304988111. View

Speeckaert R, Dugardin J, Lambert J, Lapeere H, Verhaeghe E, Speeckaert M . Critical appraisal of the oxidative stress pathway in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018; 32(7):1089-1098. DOI: 10.1111/jdv.14792. View

Venereau E, De Leo F, Mezzapelle R, Careccia G, Musco G, Bianchi M . HMGB1 as biomarker and drug target. Pharmacol Res. 2016; 111:534-544. DOI: 10.1016/j.phrs.2016.06.031. View

Cui T, Zhang W, Li S, Chen X, Chang Y, Yi X . Oxidative Stress-Induced HMGB1 Release from Melanocytes: A Paracrine Mechanism Underlying the Cutaneous Inflammation in Vitiligo. J Invest Dermatol. 2019; 139(10):2174-2184.e4. DOI: 10.1016/j.jid.2019.03.1148. View

Rashighi M, Agarwal P, Richmond J, Harris T, Dresser K, Su M . CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014; 6(223):223ra23. PMC: 4086941. DOI: 10.1126/scitranslmed.3007811. View

Andersson U, Yang H, Harris H . Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets. 2018; 22(3):263-277. DOI: 10.1080/14728222.2018.1439924. View

Vanderweil S, Amano S, Ko W, Richmond J, Kelley M, Senna M . A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2016; 76(1):150-151.e3. PMC: 5176345. DOI: 10.1016/j.jaad.2016.06.015. View

Martins C, Darrigade A, Jacquemin C, Barnetche T, Taieb A, Ezzedine K . Phenotype and function of circulating memory T cells in human vitiligo. Br J Dermatol. 2020; 183(5):899-908. DOI: 10.1111/bjd.18902. View

10.

Joshipura D, Alomran A, Zancanaro P, Rosmarin D . Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018; 78(6):1205-1207.e1. DOI: 10.1016/j.jaad.2018.02.023. View

11.

van den Boorn J, Konijnenberg D, Dellemijn T, van der Veen J, Bos J, Melief C . Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009; 129(9):2220-32. DOI: 10.1038/jid.2009.32. View

12.

Pan Y, Tian T, Park C, Lofftus S, Mei S, Liu X . Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature. 2017; 543(7644):252-256. PMC: 5509051. DOI: 10.1038/nature21379. View

13.

Furie R, Khamashta M, Merrill J, Werth V, Kalunian K, Brohawn P . Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2):376-386. PMC: 5299497. DOI: 10.1002/art.39962. View

14.

Mosenson J, Zloza A, Nieland J, Garrett-Mayer E, Eby J, Huelsmann E . Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013; 5(174):174ra28. PMC: 3912753. DOI: 10.1126/scitranslmed.3005127. View

15.

Speeckaert R, Speeckaert M, de Schepper S, van Geel N . Biomarkers of disease activity in vitiligo: A systematic review. Autoimmun Rev. 2017; 16(9):937-945. DOI: 10.1016/j.autrev.2017.07.005. View

16.

Bahloul E, Jallouli M, Garbaa S, Marzouk S, Masmoudi A, Turki H . Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus. 2017; 26(12):1304-1308. DOI: 10.1177/0961203317700486. View

17.

Webb K, Tung R, Winterfield L, Gottlieb A, Eby J, Henning S . Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol. 2015; 173(3):641-50. PMC: 4583813. DOI: 10.1111/bjd.14016. View

18.

Mercuri S, Vollono L, Paolino G . The Usefulness of Platelet-Rich Plasma (PRP) for the Treatment of Vitiligo: State of the Art and Review. Drug Des Devel Ther. 2020; 14:1749-1755. PMC: 7213865. DOI: 10.2147/DDDT.S239912. View

19.

Jacquemin C, Martins C, Lucchese F, Thiolat D, Taieb A, Seneschal J . NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo. J Invest Dermatol. 2019; 140(6):1143-1153.e5. DOI: 10.1016/j.jid.2019.11.013. View

20.

Zhuang T, Yi X, Chen J, Kang P, Chen X, Chen J . Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. Cell Death Dis. 2020; 11(6):453. PMC: 7293308. DOI: 10.1038/s41419-020-2665-z. View